Literature DB >> 20607354

Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.

Karel Zitterbart1, Hana Filkova, Lenka Tomasikova, Eva Necesalova, Iva Zambo, Dagmar Kantorova, Iva Slamova, Vladimira Vranova, Dita Zezulkova, Martina Pesakova, Zdenek Pavelka, Renata Veselska, Petr Kuglik, Jaroslav Sterba.   

Abstract

High-level amplifications of MYC genes are associated with poor outcomes in childhood medulloblastoma (MB). However, the occurrence of MYCN and MYCC copy number increases below the intense amplification pattern is rarely reported, and its clinical impact has not yet been determined. Here, we describe this phenomenon and its prognostic significance in a cohort of 29 MB patients. Using interphase fluorescence in situ hybridization (I-FISH), low-level copy number alterations, i.e. gain of MYCN, were shown in 5/27 (19%) samples, whereas amplification was revealed in only 1/27 (4%) samples. MYCC gain was revealed in 6/29 (21%) MB, while amplification was disclosed in only 2/29 (7%). Hyperploidy and co-incidence of gains in both MYC loci were frequently observed in samples with copy number aberrations. Survival analysis has clearly shown that MYC copy number increases are associated with lowered event-free survival and overall survival in MB. In the case of MYCN, this negative correlation was statistically significant. We conclude that limited numerical alterations in loci 2p24 (MYCN) and 8q24 (MYCC), as assessed by I-FISH, are present in MB with a higher frequency than high-level amplifications. Poor prognoses were observed in patients with copy number increases in MYC genes. Our data illustrate the importance of further investigations in multicenter trials to better refine the emerging genomic-based prognostic stratification in MB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607354     DOI: 10.1007/s11060-010-0289-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  51 in total

1.  Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR.

Authors:  Ryota Souzaki; Tatsuro Tajiri; Mayumi Higashi; Yoshiaki Kinoshita; Sakura Tanaka; Kenichi Kohashi; Masazumi Tsuneyoshi; Tomoaki Taguchi
Journal:  Pediatr Surg Int       Date:  2008-10       Impact factor: 1.827

2.  High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy.

Authors:  D Valteau-Couanet; B Fillipini; E Benhamou; J Grill; C Kalifa; D Couanet; J L Habrand; O Hartmann
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

3.  Expression of the c-Myc protein in childhood medulloblastoma.

Authors:  C S Bruggers; K F Tai; T Murdock; L Sivak; K Le; S L Perkins; C M Coffin; W L Carroll
Journal:  J Pediatr Hematol Oncol       Date:  1998 Jan-Feb       Impact factor: 1.289

4.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.

Authors:  David W Ellison; Olabisi E Onilude; Janet C Lindsey; Meryl E Lusher; Claire L Weston; Roger E Taylor; Andrew D Pearson; Steven C Clifford
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

5.  TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors.

Authors:  M A Grotzer; A J Janss; K Fung; J A Biegel; L N Sutton; L B Rorke; H Zhao; A Cnaan; P C Phillips; V M Lee; J Q Trojanowski
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

6.  Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.

Authors:  Jayne M Lamont; Charles S McManamy; Andrew D Pearson; Steven C Clifford; David W Ellison
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  Aggressive medulloblastoma with high-level N-myc amplification.

Authors:  F H Tomlinson; R B Jenkins; B W Scheithauer; P A Keelan; S Ritland; J E Parisi; J Cunningham; K D Olsen
Journal:  Mayo Clin Proc       Date:  1994-04       Impact factor: 7.616

8.  A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors.

Authors:  Amy Rosenfeld; Morris Kletzel; Reggie Duerst; David Jacobsohn; Paul Haut; Joanna Weinstein; Alfred Rademaker; Colleen Schaefer; Lauren Evans; Molly Fouts; Stewart Goldman
Journal:  J Neurooncol       Date:  2009-09-21       Impact factor: 4.130

Review 9.  The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.

Authors:  Barry L Pizer; Steven C Clifford
Journal:  Br J Neurosurg       Date:  2009-08       Impact factor: 1.596

Review 10.  Management of and prognosis with medulloblastoma: therapy at a crossroads.

Authors:  Roger J Packer; Gilbert Vezina
Journal:  Arch Neurol       Date:  2008-11
View more
  10 in total

Review 1.  A contemporary review of molecular candidates for the development and treatment of childhood medulloblastoma.

Authors:  N Ceren Sümer-Turanlıgil; Emel Öykü Cetin; Yiğit Uyanıkgil
Journal:  Childs Nerv Syst       Date:  2013-01-06       Impact factor: 1.475

2.  PVT1 dependence in cancer with MYC copy-number increase.

Authors:  Yuen-Yi Tseng; Branden S Moriarity; Wuming Gong; Ryutaro Akiyama; Ashutosh Tiwari; Hiroko Kawakami; Peter Ronning; Brian Reuland; Kacey Guenther; Thomas C Beadnell; Jaclyn Essig; George M Otto; M Gerard O'Sullivan; David A Largaespada; Kathryn L Schwertfeger; York Marahrens; Yasuhiko Kawakami; Anindya Bagchi
Journal:  Nature       Date:  2014-06-22       Impact factor: 49.962

3.  Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.

Authors:  Larry L Wang; Rie Suganuma; Naohiko Ikegaki; Xao Tang; Arlene Naranjo; Patrick McGrady; Wendy B London; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Robert C Seeger; Hiroyuki Shimada
Journal:  Cancer       Date:  2013-07-30       Impact factor: 6.860

4.  Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.

Authors:  Åslaug Helland; Michael S Anglesio; Joshy George; Prue A Cowin; Cameron N Johnstone; Colin M House; Karen E Sheppard; Dariush Etemadmoghadam; Nataliya Melnyk; Anil K Rustgi; Wayne A Phillips; Hilde Johnsen; Ruth Holm; Gunnar B Kristensen; Michael J Birrer; Richard B Pearson; Anne-Lise Børresen-Dale; David G Huntsman; Anna deFazio; Chad J Creighton; Gordon K Smyth; David D L Bowtell
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

5.  c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.

Authors:  André O von Bueren; Christoph Oehler; Tarek Shalaby; Katja von Hoff; Martin Pruschy; Burkhardt Seifert; Nicolas U Gerber; Monika Warmuth-Metz; Duncan Stearns; Charles G Eberhart; Rolf D Kortmann; Stefan Rutkowski; Michael A Grotzer
Journal:  BMC Cancer       Date:  2011-02-16       Impact factor: 4.430

6.  Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma.

Authors:  Jens Bunt; Nancy E Hasselt; Danny A Zwijnenburg; Jan Koster; Rogier Versteeg; Marcel Kool
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

7.  Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer.

Authors:  Man Kuen Yung; Kwok Wai Lo; Chi Wai Yip; Grace T Y Chung; Carol Y K Tong; Phyllis F Y Cheung; Tan To Cheung; Ronnie T P Poon; Samuel So; Sheung Tat Fan; Siu Tim Cheung
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

8.  Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.

Authors:  Maria B Raeder; Even Birkeland; Jone Trovik; Camilla Krakstad; Shyemaa Shehata; Steven Schumacher; Travis I Zack; Antje Krohn; Henrica Mj Werner; Susan E Moody; Elisabeth Wik; Ingunn M Stefansson; Frederik Holst; Anne M Oyan; Pablo Tamayo; Jill P Mesirov; Karl H Kalland; Lars A Akslen; Ronald Simon; Rameen Beroukhim; Helga B Salvesen
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

9.  Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.

Authors:  A N Seo; J M Yang; H Kim; S Jheon; K Kim; C T Lee; Y Jin; S Yun; J-H Chung; J H Paik
Journal:  Br J Cancer       Date:  2014-05-08       Impact factor: 7.640

10.  MicroRNA induction by copy number gain is associated with poor outcome in squamous cell carcinoma of the lung.

Authors:  Endi Xia; Sotaro Kanematsu; Yusuke Suenaga; Asmaa Elzawahry; Hitomi Kondo; Noriko Otsuka; Yasumitsu Moriya; Toshihiko Iizasa; Mamoru Kato; Ichiro Yoshino; Sana Yokoi
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.